Literature DB >> 24695102

Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease.

Jiqing Zhang1, Lee-Hwa Tai2, Carolina S Ilkow2, Almohanad A Alkayyal3, Abhirami A Ananth4, Christiano Tanese de Souza2, Jiahu Wang2, Shalini Sahi2, Lundi Ly2, Charles Lefebvre5, Theresa J Falls2, Kyle B Stephenson2, Ahmad B Mahmoud6, Andrew P Makrigiannis7, Brian D Lichty8, John C Bell4, David F Stojdl9, Rebecca C Auer10.   

Abstract

This study characterizes the ability of novel oncolytic rhabdoviruses (Maraba MG1) to boost natural killer (NK) cell activity. Our results demonstrate that MG1 activates NK cells via direct infection and maturation of conventional dendritic cells. Using NK depletion and conventional dendritic cells ablation studies in vivo, we established that both are required for MG1 efficacy. We further explored the efficacy of attenuated MG1 (nonreplicating MG1-UV(2min) and single-cycle replicating MG1-Gless) and demonstrated that these viruses activate conventional dendritic cells, although to a lesser extent than live MG1. This translates to equivalent abilities to remove tumor metastases only at the highest viral doses of attenuated MG1. In tandem, we characterized the antitumor ability of NK cells following preoperative administration of live and attenuated MG1. Our results demonstrates that a similar level of NK activation and reduction in postoperative tumor metastases was achieved with equivalent high viral doses concluding that viral replication is important, but not necessary for NK activation. Biochemical characterization of a panel of UV-inactivated MG1 (2-120 minutes) revealed that intact viral particle and target cell recognition are essential for NK cell-mediated antitumor responses. These findings provide mechanistic insight and preclinical rationale for safe perioperative virotherapy to effectively reduce metastatic disease following cancer surgery.

Entities:  

Mesh:

Year:  2014        PMID: 24695102      PMCID: PMC4088996          DOI: 10.1038/mt.2014.60

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  41 in total

1.  [Covalent-bound aggregates of equine venezuelan encephalomyelitis virus induced by UV-irradiation].

Authors:  Iu A Smirnov; S P Kapitulets; A M Makhov
Journal:  Mol Gen Mikrobiol Virusol       Date:  1990-06

Review 2.  NK cells in innate immunity.

Authors:  Jessica A Hamerman; Kouetsu Ogasawara; Lewis L Lanier
Journal:  Curr Opin Immunol       Date:  2005-02       Impact factor: 7.486

Review 3.  NK cell recognition.

Authors:  Lewis L Lanier
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

4.  Peri-operative modulation of cellular immunity in patients with colorectal cancer.

Authors:  P H Nichols; C W Ramsden; U Ward; L K Trejdosiewicz; N S Ambrose; J N Primrose
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

5.  Tolerance and feasibility of perioperative treatment with interferon-alpha 2a in advanced cancers.

Authors:  G Houvenaeghel; F Bladou; J L Blache; D Olive; G Monges; J Jacquemier; H Chaudet; J R Delpero; G Guérinel
Journal:  Int Surg       Date:  1997 Apr-Jun

6.  Phase I-II randomized study on prehepatectomy recombinant interleukin-2 immunotherapy in patients with metastatic carcinoma of the colon and rectum.

Authors:  D Elias; F Farace; F Triebel; J M Hattchouel; J P Pignon; A Lecesne; P Rougier; P Lasser; P Duvillard; B Escudier
Journal:  J Am Coll Surg       Date:  1995-10       Impact factor: 6.113

7.  Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer.

Authors:  P H Nichols; C W Ramsden; U Ward; P C Sedman; J N Primrose
Journal:  Cancer Res       Date:  1992-10-15       Impact factor: 12.701

8.  Interleukin-2 (IL-2) augments host cellular immune reactivity in the perioperative period in patients with malignant disease.

Authors:  D J Deehan; S D Heys; J Ashby; O Eremin
Journal:  Eur J Surg Oncol       Date:  1995-02       Impact factor: 4.424

9.  Surgical stress promotes the development of cancer metastases by a coagulation-dependent mechanism involving natural killer cells in a murine model.

Authors:  Rashmi Seth; Lee-Hwa Tai; Theresa Falls; Christiano T de Souza; John C Bell; Marc Carrier; Harold Atkins; Robin Boushey; Rebecca A Auer
Journal:  Ann Surg       Date:  2013-07       Impact factor: 12.969

10.  VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

Authors:  David F Stojdl; Brian D Lichty; Benjamin R tenOever; Jennifer M Paterson; Anthony T Power; Shane Knowles; Ricardo Marius; Jennifer Reynard; Laurent Poliquin; Harold Atkins; Earl G Brown; Russell K Durbin; Joan E Durbin; John Hiscott; John C Bell
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

View more
  30 in total

1.  Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.

Authors:  Sébastien A Felt; Valery Z Grdzelishvili
Journal:  J Gen Virol       Date:  2017-12       Impact factor: 3.891

Review 2.  Killers 2.0: NK cell therapies at the forefront of cancer control.

Authors:  Jonathan J Hodgins; Sarwat T Khan; Maria M Park; Rebecca C Auer; Michele Ardolino
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

Review 3.  Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones.

Authors:  Nikolas Tim Martin; John Cameron Bell
Journal:  Mol Ther       Date:  2018-04-05       Impact factor: 11.454

4.  Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses.

Authors:  Norman Woller; Engin Gürlevik; Bettina Fleischmann-Mundt; Anja Schumacher; Sarah Knocke; Arnold M Kloos; Michael Saborowski; Robert Geffers; Michael P Manns; Thomas C Wirth; Stefan Kubicka; Florian Kühnel
Journal:  Mol Ther       Date:  2015-06-26       Impact factor: 11.454

5.  Murine Tumor Models for Oncolytic Rhabdo-Virotherapy.

Authors:  Theresa Falls; Dominic Guy Roy; John Cameron Bell; Marie-Claude Bourgeois-Daigneault
Journal:  ILAR J       Date:  2016

6.  Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy.

Authors:  Weizhou Hou; Padma Sampath; Juan J Rojas; Steve H Thorne
Journal:  Cancer Cell       Date:  2016-06-30       Impact factor: 31.743

Review 7.  Oncolytic viruses and immunity.

Authors:  Shyambabu Chaurasiya; Nanhai G Chen; Yuman Fong
Journal:  Curr Opin Immunol       Date:  2018-03-16       Impact factor: 7.268

Review 8.  Metastasis Prevention: Focus on Metastatic Circulating Tumor Cells.

Authors:  Maxim E Menyailo; Ustinia A Bokova; Elena E Ivanyuk; Anna A Khozyainova; Evgeny V Denisov
Journal:  Mol Diagn Ther       Date:  2021-07-21       Impact factor: 4.074

Review 9.  Attacking Postoperative Metastases using Perioperative Oncolytic Viruses and Viral Vaccines.

Authors:  Lee-Hwa Tai; Rebecca Auer
Journal:  Front Oncol       Date:  2014-08-12       Impact factor: 6.244

Review 10.  Oncolytic viruses as anticancer vaccines.

Authors:  Norman Woller; Engin Gürlevik; Cristina-Ileana Ureche; Anja Schumacher; Florian Kühnel
Journal:  Front Oncol       Date:  2014-07-21       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.